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Abstract
Background: Chronic kidney disease (CKD) is strongly associated with adverse outcomes after percutaneous coronary
intervention (PCI). There are limited data on the effectiveness of drug-eluting stents (DES) in patients with CKD.
Methodology/Principal Findings: Of 3,752 consecutive patients enrolled in the Guthrie PCI Registry between 2001 and
2006, 436 patients with CKD - defined as a creatinine clearance ,60 mL/min - were included in this study. Patients who
received DES were compared to those who received bare metal stents (BMS). Patients were followed for a mean duration of
3 years after the index PCI to determine the prognostic impact of stent type. Study end-points were all-cause death,
myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis (ST) and the composite of major adverse
cardiovascular events (MACE), defined as death, MI or TVR. Patients receiving DES in our study, by virtue of physician
selection, had more stable coronary artery disease and had lower baseline risk of thrombotic or restenotic events. Kaplan-
Meier estimates of proportions of patients reaching the end-points were significantly lower for DES vs. BMS for all-cause
death (p=0.0008), TVR (p=0.029) and MACE (p=0.0015), but not MI (p=0.945) or ST (p=0.88). Multivariable analysis with
propensity adjustment demonstrated that DES implantation was an independent predictor of lower rates of all-cause death
(hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.25–0.92), TVR (HR 0.50, 95% CI 0.27–0.94) and MACE (HR 0.62, 95% CI
0.41–0.94).
Conclusions: In a contemporary PCI registry, selective use of DES in patients with CKD was safe and effective in the long
term, with lower risk of all-cause death, TVR and MACE and similar risk of MI and ST as compared with BMS. The mortality
benefit may be a result of selection bias and residual confounding, or represent a true finding; a hypothesis that warrants
clarification by randomized clinical trials.
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Introduction
In patients with coronary artery disease, the presence of chronic
kidney disease (CKD) is strongly associated with increased
mortality and an increased incidence of major adverse cardiovas-
cular events (MACE) after percutaneous coronary intervention
(PCI) [1,2,3].
Coronary stents have substantially improved the efficacy of
percutaneous revascularization. Drug-eluting stents (DES) have
further reduced the rates of in-stent restenosis and repeat
revascularization compared to bare metal stents (BMS) [4,5,6].
However, there are limited data on the safety and efficacy
o fD E Si np a t i e n t sw i t hC K Db e c a u s et h e s ep a t i e n t sa r e
systematically excluded from major interventional cardiology
trials [7,8,9].
The purpose of the current study was to determine the long-
term effectiveness of DES in patients with CKD. Using a
prospective registry of consecutive patients undergoing PCI at
our tertiary care academic hospital, we evaluated clinical outcomes
following DES use compared with BMS use in patients with
CKD.
Methods
Ethics
Data were analyzed anonymously and informed consent was
neither required nor obtained. Guthrie Clinic’s Institutional
Review Board approved the study and agreed that informed
consent was not required. Approval was neither required nor
obtained from ethics committees.
Patient Population
The Guthrie PCI Registry is a prospective, observational
registry of all patients undergoing PCI at our center. As described
previously [10,11], demographic, clinical, angiographic, laborato-
ry values and in-hospital outcomes are collected by dedicated
specially trained nursing personnel, in a standardized fashion in
accordance with American College of Cardiology National
Cardiovascular Data Registry (ACC-NCDR) definitions [12].
Longitudinal follow-up information is obtained annually using
multiple concurrent approaches including patient follow-up visits,
surveillance of medical records, contact with primary care
providers, telephone contacts with registry participants or next-
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Master File.
3,752 patients underwent PCI procedures at our center and
were enrolled in the Registry between January 2001 and
December 2006. Patients were excluded from the current study
if they had undergone any prior PCI at our institution during the
study period, were diagnosed with cardiogenic shock prior to PCI,
had not received a stent or had received a combination of DES
and BMS. Patients were also excluded if their baseline creatinine
was not available. Based on these exclusion criteria, 2,376 patients
remained, of which, 436 had a creatinine clearance of ,60 mL/
min and constituted the cohort for the current study (Figure 1).
Study subjects were assigned to either the DES group or the BMS
group according to the stent type used during the index PCI.
Assessment of Renal Function
Baseline creatinine values obtained before the index PCI were
used to calculate creatinine clearance according to the Cockcroft-
Gault formula: creatinine clearance (milliliters/minute) = [(140-
age) X weight (kilograms)]/[serum creatinine (milligrams/deciliter)
x 72], corrected in women by a factor of 0.85 [13]. A creatinine
clearance of ,60 mL/min, corresponding to at least moderate
CKD as per the National Kidney Foundation guidelines [14], was
used to define patients with CKD for the purposes of this study.
While the Modification of Diet in Renal Disease (MDRD) formula
is more accurate than the Cockcroft-Gault formula in estimating
glomerular filtration rates ,60 mL/min, the Cockcroft-Gault
formula was used for assessment of renal function since it has been
shown to identify more patients at risk for adverse clinical
outcomes following non-ST-segment elevation acute coronary
syndromes compared to the MDRD formula [15].
Prevention of Contrast-mediated Renal Dysfunction
At our institution, patients deemed at risk for contrast-mediated
renal dysfunction are treated with intravenous sodium bicarbonate
solution (150 mEq sodium bicarbonate in 1000 ml 5% dextrose in
water) at 3 ml/kg/hour for 1 hour prior to the PCI, and at 1 ml/
kg/hour for 6 hours following the PCI. N-acetylcysteine 600 mg
twice a day for 4 doses is also used in combination with
intravenous sodium bicarbonate solution. Our protocols recom-
mend prophylactic treatment for all patients with estimated
glomerular filtration rates ,60 mL/min. Patients undergoing
urgent or emergent PCI or those who are deemed unsuitable for
aggressive hydration (due to left ventricular dysfunction, conges-
tive heart failure or uncontrolled hypertension) receive abbreviated
regimens of intravenous sodium bicarbonate and N-acetylcysteine.
Definitions
As outlined in the ACC-NCDR [12], procedures were classified
as elective or non-elective based on the presentation (stable angina
vs. unstable angina, NSTEMI or STEMI) and risk of infarction or
death. Elective procedures could have been performed on an
outpatient basis or during a subsequent hospitalization without
significant risk of infarction or death. For stable inpatients, elective
procedures were performed during the hospitalization for
convenience and ease of scheduling and not because the patients’
Figure 1. Study Patients. BMS = bare metal stent; Creatinine clearance = creatinine clearance; DES = drug-eluting stents; PCI = percutaneous
coronary intervention.
doi:10.1371/journal.pone.0015070.g001
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other procedures were classified non-elective. The study outcomes
were all-cause death, myocardial infarction (MI), target vessel
revascularization (TVR), stent thrombosis (ST) and the composite
of major adverse cardiovascular events (MACE), defined as death,
MI or TVR. Standard definitions, outlined in the ACC-NCDR
[12], were used to define peri-procedural complications. MI was
defined as the occurrence of 2 or more of the following: chest pain,
abnormal electrocardiographic changes suggestive of acute
myocardial infarction, or elevated cardiac biomarkers. TVR was
defined as PCI performed in a vessel treated during the index
procedure or any coronary artery bypass grafting procedure
performed after the index procedure, due to recurrence of angina
or other evidence of ischemia. ST for the purposes of the current
study included either definite or probable ST as defined by the
Academic Research Consortium [16].
Statistical Analysis
Continuous data are presented as mean 6 standard deviation.
Wilcoxon rank tests were used to compare mean values of
continuous data between 2 groups. Categorical variables are
reported as percentages and comparisons were made using Chi-
square tests where appropriate (expected frequency .5), otherwise
Fisher’s Exact tests were used. Using the Kaplan-Meier method,
event-free survival curves were constructed for all study outcomes
and compared using log-rank tests. Because the patients were not
randomly assigned to receive either DES or BMS, the propensity
to receive a DES was estimated by performing multivariate logistic
regression using all baseline variables that showed a univariate
association (p,0.10) with DES implantation. To assess the impact
of choice of stent type on all-cause death, TVR and MACE, we
performed Cox proportional hazards regression analyses. Dura-
tion of follow-up was truncated at 4 years (1,460 days). In
multivariable Cox regression analyses, the initial model included
stent type (DES vs. BMS), propensity score for receiving DES and
all variables that showed a significant relation with stent type
(p,0.10). Backward stepwise regression was performed, eliminat-
ing variables that showed no significant association (p.0.05) with
the outcome. The variable denoting stent type was retained in the
model irrespective of its statistical significance. In the final models,
we estimated adjusted hazards ratios (HR) and 95% confidence
intervals (CI) denoting the impact of stent type on the study
outcomes. All statistical tests were 2-tailed and p,0.05 was
regarded as significant. All analyses were conducted using The
SASH System for Windows version 9.1.3, Service Pack 4, Cary,
North Carolina, USA.
Results
Of 2,376 consecutive all-comer patients enrolled in the Guthrie
PCI Registry with a baseline serum creatinine measurement, index
procedure during the study period, without cardiogenic shock and
implantation of either DES or BMS, 18% (436) had a creatinine
clearance of ,60 mL/min. Of these 436 patients, 222 (51%) patients
had received DES and 214 (49%) patients had received BMS.
Clinical, Procedural, and Angiographic Characteristics
Tables 1 and 2 present the clinical, and procedural and
angiographic characteristics, respectively, of the study patients,
stratified by the study group.
Table 1. Clinical Characteristics.
Characteristic
All
(n=436)
BMS
(n=214)
DES
(n=222) p-Value
Age, years 71+/210 73+/210 69+/211 0.0003
Male 87 (20%) 49 (23%) 38 (17%) 0.13
Weight, kilograms 69+/211 67+/211 70+/212 0.0044
Body surface area, meters squared 1.73+/20.15 1.71+/20.16 1.75+/20.15 0.015
Diabetes mellitus 90 (21%) 33 (15%) 57 (26%) 0.0082
Cigarette smoking 100 (22%) 48 (22%) 52 (23%) 0.61
Hypertension 296 (68%) 143 (67%) 153 (69%) 0.64
Dyslipidemia 297 (68%) 133 (62%) 164 (74%) 0.0086
Peripheral vascular disease 58 (13%) 30 (14%) 28 (13%) 0.67
Cerebrovascular disease 37 (8%) 21 (10%) 16 (7%) 0.33
Prior MI 81 (19%) 47 (22%) 34 (15%) 0.074
Prior CABG 65 (15%) 37 (17%) 28 (13%) 0.17
Prior PCI 57 (13%) 25 (12%) 32 (14%) 0.40
Heart failure 35 (8%) 19 (9%) 16 (7%) 0.52
Non-elective procedure 270 (62%) 153 (71%) 117 (53%) ,0.0001
Presented with STEMI 79 (18%) 50 (23%) 29 (13%) 0.005
Presented with NSTEMI 111 (25%) 59 (28%) 52 (23%) 0.32
Received thrombolytic drug before PCI 25 (6%) 20 (9%) 5 (2%) 0.0016
Creatinine clearance, mL/min 47+/294 6 +/210 47+/28 0.17
p,0.05 for pairwise comparison between DES and BMS groups.
Continuous variables are expressed as mean 6 standard deviation (median). Categorical variables are expressed counts (percentages).
BMS = bare metal stent; CABG = coronary artery bypass graft surgery; DES = drug-eluting stents; MI = myocardial infarction; NSTEMI = non-ST-segment elevation
myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.
doi:10.1371/journal.pone.0015070.t001
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younger (69 vs. 73 years; p=0.0003), heavier (70 vs. 67 kg;
p=0.0044), diabetic (26% vs. 15%; p=0.0082) and dyslipidemic
(74% vs. 62%; p=0.0086) than those who received BMS. They
were also more likely to have had smaller vessels (3.0 mm vs.
3.2 mm; p=0.0003), higher LVEF (50% vs. 47%; p=0.015) and
successful PCI (99% vs. 92%; p=0.0002).
Patients who received DES were less likely to have presented
with acute STEMI (13% vs. 23%; p=0.005), had a non-elective
procedure (53% vs. 71%; p,0.0001) and received thrombolytic
therapy prior to the PCI (2% vs. 9%; p=0.0016) than those who
received BMS. They were also less likely to have had lesions
longer than 28 mm (9.5% vs. 16%; p=0.041) and received
glycoprotein IIb/IIIa inhibitor drugs during PCI (67% vs. 87%;
p,0.0001).
Mean creatinine clearance was not significantly different
between the DES and BMS groups (47 vs. 46 mL/min; p=0.17).
Propensity score
Based on the univariate analyses, a step-down logistic regression
analysis was done to create a propensity score for receiving DES
instead of BMS. Included in the first step were all the variables
from univariate analyses with p,0.10. The least significant
variable was dropped at each step until only those variables with
p,0.05 remained in the final model. Using the parameter
estimates for creating a propensity score, the following formula
was reached for the propensity score:
Propensity score =4.8383+ dyslipidemia x (0.5314)+ thrombo-
lytic use x (21.0176)+ use of glycoprotein IIb/IIIa inhibitor drugs
x( 21.3345)+ age x (20.0306)+ weight x (0.0246)+ vessel diameter
x( 21.1752).
The c statistic was 0.73 and the Global WALD statistic was 58
with 6 degrees of freedom (p,0.0001).
Outcomes
The mean follow-up period was 2.9761.14 (median 3.39) years
(range 0 to 4 years). No patients were lost to follow-up.
Kaplan–Meier Analyses
Kaplan–Meier curves are shown in Figure 2. Compared to
BMS patients, DES patients had significantly lower rates of all-
cause death (p=0.0008, Figure 2A) without lower rates of MI
(p=0.94, Figure 2B) or ST (p=0.88, Figure 2C). DES patients also
had significantly lower rates of TVR (p=0.029, Figure 2D) and
MACE (p=0.0015, Figure 2E) compared to BMS patients.
Multivariable Analysis
Multivariable analysis with propensity adjustment (Figure 3)
demonstrated that DES implantation was an independent
predictor of lower all-cause death (hazard ratio [HR] 0.48, 95%
confidence interval [CI] 0.25–0.92), TVR (HR 0.50, 95% CI
0.27–0.94) and MACE (HR 0.62, 95% CI 0.41–0.94).
Discussion
We found that the use of DES in consecutive patients with CKD
undergoing PCI was associated with improved outcomes in terms of
all-cause death, TVR and MACE. We also found that DES were not
associated with a higher risk of ST compared to BMS in these patients.
Finally, DES were not associated with an increased risk of MI.
We found that 18% of all-comers undergoing PCI at our
institution had creatinine clearance ,60 mL/min or at least
moderate CKD by the National Kidney Foundation guidelines
[14]. This number is not surprising considering that more than 8%
of the adult population of the United States is estimated to have at
least moderate CKD [17].
Several studies have shown that patients with CKD who undergo
revascularization by PCIand stenting consistently have worse short-
and long-term outcomes relative to patients without CKD [1,2].
Many of these studies included patients who had PCI before the
advent of DES. Studies that included patients with DES were small,
single-centered, observational analyses. The follow-up period was
usually12 monthsorlesswithonly 2 studies having follow-uplonger
than 12 months [18,19]. There has been no randomized clinical
trial investigating the efficacy of DES in patients with CKD.
We found that DES, compared with BMS, were associated with
reduced risk of TVR. This finding echoes those of large studies of
DES in the general population [6]. We found the use of DES to be
a significant independent predictor of reduced all-cause mortality,
compared to BMS. This reduction in mortality with DES was not
accompanied by reductions in rates of MI or ST but was
accompanied by lower rates of restenosis. The absolute benefits of
DES compared to BMS may be greater in CKD patients given
their higher restenosis risk, which can potentially contribute to the
survival advantage. Patients with CKD, especially end-stage renal
disease, have higher in-stent restenosis rates, irrespective of the
type of stent [2]. Exaggerated neointimal growth in CKD patients
has been attributed to higher rates of co-morbidities such as
diabetes mellitus, greater atherosclerotic burden, vascular calcifi-
cation, stent under expansion, chronic systemic inflammation,
granulocyte activation and oxidative stress [2,20,21].
However, it is difficult to explain the lower mortality among DES
patients solely by the reduced rates of restenosis. While patients
receiving DES in our study were at higher risk with respect to rates of
diabetes mellitus and hyperlipidemia, they were at lower risk with
respect to rates of acute ST-segment elevation MI (STEMI), lesion
characteristics, left ventricular function and success of PCI. Conse-
quently, patients receiving DES in our study, by virtue of selection bias,
had more stable coronary artery disease and lower baseline risk of
thrombotic or restenotic events. The role of DES during PCI for
STEMI has been controversial [22] and the lower use of DES in
patients with acute MI reflects contemporary clinical practice.
Table 2. Procedural and Angiographic Characteristics.
Characteristic
All
(n=436)
BMS
(n=214)
DES
(n=222) p-Value
LVEF 49+/212 47+/213 50+/211 0.015
Vessel diameter, mm 3.1+/20.5 3.2+/20.6 3.0+/20.4 0.0003
Multivessel PCI 47 (11%) 27 (13%) 20 (9%) 0.22
Lesion length .28 mm 55 (13%) 34 (16%) 21 (9.5%) 0.041
Chronic total occlusion 6 (1.3%) 2 (0.9%) 4 (1.8%) 0.69
Bifurcation lesion 10 (2.2%) 2 (0.9%) 8 (3.6%) 0.11
Ostial lesion 23 (5.3%) 9 (4%) 14 (6%) 0.33
Restenotic lesion 8 (1.8%) 2 (0.9%) 6 (2.7%) 0.29
Use of IABP during PCI 19 (4.3%) 12 (6%) 7 (3%) 0.19
Use of GPI during PCI 335 (77%) 186 (87%) 149 (67%) ,0.0001
Successful PCI 414 (95%) 195 (92%) 219 (99%) 0.0002
p,0.05 for pairwise comparison between DES and BMS groups.
Continuous variables are expressed as mean 6 standard deviation (median).
Categorical variables are expressed counts (percentages).
BMS = bare metal stent; DES = drug-eluting stents; GPI = glycoprotein IIb/IIIa
inhibitor; IABP = intra-aortic balloon pump; LVEF = left ventricular ejection
fraction; PCI = percutaneous coronary intervention.
doi:10.1371/journal.pone.0015070.t002
DES in CKD
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with respect to the nonrandomized choice of either DES or BMS.
While multivariable adjustment and propensity matching mitigate
the effect of measured confounders on the DES vs. BMS effect
estimate, these approaches have limited ability to address the
influence of unmeasured confounders. A survival benefit from
DES has not been observed in randomized controlled trials. Thus,
unmeasured confounders likely contribute to the reduction in
mortality with DES in observational studies of DES vs. BMS use,
including the current study. In a meta-analysis of 31 observational
studies that included 169,595 all-comer patients, DES vs. BMS use
was associated with an 18 to 22% reduction in mortality [6], but
this effect was not noted in a meta-analysis of 21 randomized
clinical trials that included 8,867 patients [6].
Figure 2. Kaplan-Meier Curves of Estimated Cumulative Incidence of Outcomes. The estimated cumulative incidences of all-cause death
(A), MI (B), ST (C), TVR (D) and MACE (E) are shown. BMS = bare metal stent; DES = drug-eluting stents; MACE = major adverse cardiovascular events;
PCI = percutaneous coronary intervention; MI = myocardial infarction; ST = stent thrombosis; TVR = target vessel revascularization.
doi:10.1371/journal.pone.0015070.g002
DES in CKD
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use of DES compared to BMS reduced the risk of all-cause
mortality at 17 months in the study by Zhang et al. [19], and did
not reduce mortality at 4 years in the study by Appleby et al. [18].
While our findings are concordant with those of Zhang et al., they
did not use any type of statistical designs (matching, covariate
adjustment, or propensity-based adjustment) to adjust for
differences between the DES and BMS patients. The discordance
between our findings and those of Appleby et al. are likely due to
differences in the clinical and angiographic characteristics of
patients studied, duration of follow-up and potentially dissimilar
unmeasured confounders. Of note, Appleby et al. found a
significant survival benefit from DES compared to BMS in the
first year (p=0.002), with catch-up at 2 years (p=0.057).
In the general population, DES are associated with an increased
risk of late ST compared with BMS [23,24,25,26]. However, we
did not find a higher incidence of ST with DES relative to BMS at
3 years. This finding is notable since CKD has been described as a
risk factor for ST after DES implantation [27,28,29]. Nonetheless,
there have been no previous studies comparing the long-term
incidence of ST with DES vs. BMS in patients with CKD. ST was
not evaluated in the 2 studies of DES vs. BMS in CKD patients,
with follow-up of .12 months [18,19].
Two studies have compared ST at 12 months between DES and
BMS in CKD patients [30,31]. In the study by Halkin et al., there
were no differences in the rates of ST between DES and BMS at 12
months in either patients with mild CKD (creatinine clearance 60 to
89 mL/min) or patients with at least moderate CKD (creatinine
clearance ,60 mL/min) [30]. Okada et al. only included patients on
hemodialysis and found no significant difference in the rates of ST at
12 months between DES and BMS [31]. Our findings corroborate
data from these 2 studies and suggest that there is no increase in the
risk of ST at least up to 3 years after DES implantation in patients
with creatinine clearance ,60 mL/min. A possible explanation for
this observation might be that the baseline endothelial dysfunction
and inflammatory milieu in patients with CKD increases the risk of
ST to similar degrees with DES and BMS.
Limitations
As with any observational study, our study has the potential for
unmeasured confounding. Creatinine clearance was assessed from a
single measurement of pre-procedure creatinine. Therefore, the
estimated creatinine clearance used in the study may not represent
the true baseline renal function at the time of the index procedure
and thus, misclassification bias is possible. Only first-generation
DES were included in this study. To avoid confounding from
multiple stent types, we excluded patients with prior PCI - a high-
risk group of patients. We did not account for differences in the use
of long-term medications such as antiplatelet therapy between the
DES and BMS groups. The longer duration of dual antiplatelet
therapy required with DES [32] may reduce long-term adverse
event rates independently of stent selection [33]. We did not study
outcomes stratified by every stage of CKD and for patients on
dialysis. While it is possible that patients with stages 4 and 5 CKD
may have worse outcomes relative to those of stage 3 CKD, and
patientswithstages1and2CKDmayhave worse outcomesrelative
to patients without CKD, our goal was to study the utility of DES in
a broad group of patients with CKD that are at the greatest risk for
atherosclerotic cardiovascular disease and need for revasculariza-
tion, that is, patients with creatinine clearance,60 mL/min[1,14].
Finally, we did not include data about the etiology of renal
dysfunction in patients with creatinine clearance ,60 mL/min.
Summary
In a contemporary PCI registry, selective use of DES in patients
with CKD was safe and effective in the long term, with lower risk
of all-cause death, TVR and MACE and similar risk of MI and ST
as compared with BMS. The mortality benefit may be a result of
selection bias and residual confounding, or represent a true
finding; a hypothesis that needs to be tested using randomized
clinical trials. Given the increasing prevalence of CKD, the
potential for improved ischemic outcomes and survival after PCI
may have important implications for individual patients and for
public health policy recommendations.
Author Contributions
Conceived and designed the experiments: CS KJH. Performed the
experiments: CS JB PO. Analyzed the data: JB. Wrote the paper: CS KJH.
References
1. Widimsky P, Rychlik I (2010) Renal disease and acute coronary syndrome.
Heart 96: 86–92.
2. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, et al. (2009)
The scope of coronary heart disease in patients with chronic kidney disease. J Am
Coll Cardiol 53: 2129–2140.
3. U.S. Renal Data System USRDS (2009) Annual Data Report: Atlas of Chronic
Kidney Disease and End-Stage Renal Disease in the United States. National
Institutes of Health, National Institute of Diabetes and Digestive and Kidney
Diseases, Bethesda, MD, 2009.
4. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al. (2003)
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native
coronary artery. N Engl J Med 349: 1315–1323.
5. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, et al. (2004) A
polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
N Engl J Med 350: 221–231.
6. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, et al. (2009) Safety and
efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of
randomized trials and observational studies. Circulation 119: 3198–3206.
Figure 3. Multivariable Analysis with Propensity Adjustment
Denoting the Impact of Stent Type on All-Cause Death, TVR
and MACE. BMS = bare metal stent; DES = drug-eluting stents;
MACE = major adverse cardiovascular events; TVR = target vessel
revascularization.
doi:10.1371/journal.pone.0015070.g003
DES in CKD
PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e150707. Coca SG, Krumholz HM, Garg AX, Parikh CR (2006) Underrepresentation of
renal disease in randomized controlled trials of cardiovascular disease. JAMA
296: 1377–1384.
8. Novak JE, Szczech LA (2008) Feast and famine: epidemiology and clinical trials
in chronic kidney disease. J Am Soc Nephrol 19: 2–4.
9. Himmelfarb J (2007) Chronic kidney disease and the public health: gaps in
evidence from interventional trials. JAMA 297: 2630–2633.
10. Harjai KJ, Shenoy C, Orshaw P, Boura J (2009) Dual antiplatelet therapy for
more than 12 months after percutaneous coronary intervention: insights from
the Guthrie PCI Registry. Heart 95: 1579–1586.
11. Shenoy C, Orshaw P, Devarakonda S, Harjai KJ (2009) Occurrence, predictors,
and outcomes of post-percutaneous coronary intervention thrombocytopenia in
an unselected population. J Interv Cardiol 22: 156–162.
12. National Cardiovascular Data Registry DED, Technology Downloads and Risk
Adjustment Available at: http://www.ncdr.com/WebNCDR/elements.aspx.
Last accessed August 18, 2010.
13. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum
creatinine. Nephron 16: 31–41.
14. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, et al. (2003) National Kidney
Foundation practice guidelines for chronic kidney disease: evaluation, classifi-
cation, and stratification. Ann Intern Med 139: 137–147.
15. Melloni C, Peterson ED, Chen AY, Szczech LA, Newby LK, et al. (2008)
Cockcroft-Gault versus modification of diet in renal disease: importance of
glomerular filtration rate formula for classification of chronic kidney disease in
patients with non-ST-segment elevation acute coronary syndromes. J Am Coll
Cardiol 51: 991–996.
16. Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, et al. (2007) Stent
thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med
356: 1020–1029.
17. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, et al. (2007) Prevalence of
chronic kidney disease in the United States. JAMA 298: 2038–2047.
18. Appleby CE, Ivanov J, Lavi S, Mackie K, Horlick EM, et al. (2009) The adverse
long-term impact of renal impairment in patients undergoing percutaneous
coronary intervention in the drug-eluting stent era. Circ Cardiovasc Interv 2:
309–316.
19. Zhang R, Ni J, Zhang J, Hu J, Yang Z, et al. (2006) Long term clinical outcomes
in patients with moderate renal insufficiency undergoing stent based percuta-
neous coronary intervention. Chin Med J (Engl) 119: 1176–1181.
20. Ishio N, Kobayashi Y, Takebayashi H, Iijima Y, Kanda J, et al. (2007) Impact of
drug-eluting stents on clinical and angiographic outcomes in dialysis patients.
Circ J 71: 1525–1529.
21. Nakazawa G, Tanabe K, Aoki J, Yamamoto H, Higashikuni Y, et al. (2007)
Impact of renal insufficiency on clinical and angiographic outcomes following
percutaneous coronary intervention with sirolimus-eluting stents. Catheter
Cardiovasc Interv 69: 808–814.
22. Spaulding C, Rosencher J, Varenne O (2010) Use of drug eluting stents in ST
segment elevation myocardial infarction. Heart 96: 1073–1077.
23. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, et al. (2006) Late
thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.
Am J Med 119: 1056–1061.
24. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P,
et al. (2006) Late clinical events after clopidogrel discontinuation may limit the
benefit of drug-eluting stents: an observational study of drug-eluting versus bare-
metal stents. J Am Coll Cardiol 48: 2584–2591.
25. Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, et al. (2007) Stent
thrombosis, myocardial infarction, and death after drug-eluting and bare-metal
stent coronary interventions. J Am Coll Cardiol 50: 463–470.
26. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, et al. (2007)
Outcomes associated with drug-eluting and bare-metal stents: a collaborative
network meta-analysis. Lancet 370: 937–948.
27. Lasala JM, Cox DA, Dobies D, Baran K, Bachinsky WB, et al. (2009) Drug-
eluting stent thrombosis in routine clinical practice: two-year outcomes and
predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv 2:
285–293.
28. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al. (2005)
Incidence, predictors, and outcome of thrombosis after successful implantation
of drug-eluting stents. JAMA 293: 2126–2130.
29. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, et al. (2006)
Correlates and long-term outcomes of angiographically proven stent thrombosis
with sirolimus- and paclitaxel-eluting stents. Circulation 113: 1108–1113.
30. Halkin A, Mehran R, Casey CW, Gordon P, Matthews R, et al. (2005) Impact of
moderate renal insufficiency on restenosis and adverse clinical events after
paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-
IV Trial. Am Heart J 150: 1163–1170.
31. Okada T, Hayashi Y, Toyofuku M, Imazu M, Otsuka M, et al. (2008) One-year
clinical outcomes of dialysis patients after implantation with sirolimus-eluting
coronary stents. Circ J 72: 1430–1435.
32. King SB, 3rd, Smith SC, Jr., Hirshfeld JW, Jr., Jacobs AK, Morrison DA, et al.
(2008) 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update
for Percutaneous Coronary Intervention: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines:
2007 Writing Group to Review New Evidence and Update the ACC/AHA/
SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing
on Behalf of the 2005 Writing Committee. Circulation 117: 261–295.
33. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, et al. (2007) Patients
with prior myocardial infarction, stroke, or symptomatic peripheral arterial
disease in the CHARISMA trial. J Am Coll Cardiol 49: 1982–1988.
DES in CKD
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e15070